![]() ![]() Stover: First-line therapy for hormone receptor positive HER2-negative metastatic breast cancer remains endocrine therapy plus CDK4/6 inhibitors. ![]() He also discusses the post hoc analysis findings from CALGB 40502.Ĭan you summarize the main points of your presentation? In an interview with Targeted Oncology™, Stover, breast medical oncologist at the Ohio State University Comprehensive Cancer Center, highlighted the objective to enhance delivery of endocrine therapy plus CDK4/6 inhibitors to patients with hormone receptor (HR)-positive, HER2-negative breast cancer by utilizing biomarker assessments as a guide to interchange or cease treatment at the most favorable time. ![]() Moreover, low vs high immune activation significantly correlated worse progression-free survival (hazard ratio, 1.34 95% CI 1.1-1.63, P =0.004) and overall survival (hazard ratio, 1.32 95% CI 1.07-1.63, P =0.009). Stover, MD showed that in 582 patients with breast cancer, stromal TILs made up a mean of 13.3% primary tumors vs 8.4% metastatic tumors ( P =3e-4). 1 These findings come from the post hoc analysis of the phase 3 CALGB (Alliance) 40502 study (NCT00785291).Īt the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, the results presented by Daniel G. As measured by stromal tumor infiltrating lymphocytes (TILs), immune activation was considerably lower in metastatic breast tumors compared with primary breast tumors, and it appeared to vary according to the metastatic site. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |